Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 720 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dry Eye Disease Clear all
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04201574
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ALY688 0.1%, ALY688 0.4%, Vehicle
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 9, 2026, 5:02 PM EDT
Terminated Phase 4 Interventional

Performance of Systane PRO Versus Refresh Optive Mega-3

NCT06975891
View directory record Official record
Conditions
Dry Eye
Interventions
Systane PRO, Refresh Optive MEGA-3
Drug
Lead sponsor
Scripps Poway Eyecare and Optometry
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

NCT07780890
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG), Dry Eye Disease (DED), Keratoconus, Lasik Eye Surgery
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 79 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 2Phase 3 Interventional

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04899518
View directory record Official record
Conditions
Dry Eye
Interventions
ALY688 Ophthalmic Solution
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

NCT01163643
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, Placebo Comparator: Vehicle, 1% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension AM, 2% BOL-303242-X ophthalmic suspension PM
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 9, 2026, 5:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye

NCT04493658
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndromes, Ocular Surface Disease, Sjogren's Syndrome
Interventions
Questionnaires, Tear fluid sampling, Impression Cytology
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 9, 2026, 5:02 PM EDT
Recruiting No phase listed Observational

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

NCT07144137
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Mountain View, California • Oak Forest, Illinois • Springfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 4 Interventional

SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease

NCT07243275
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
SYSTANE® PRO, MIEBO™ (Perfluorohexyloctane, PFHO)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Newport Beach, California • Bloomington, Indiana • Pittsburg, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

NCT02975557
View directory record Official record
Conditions
Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions
Brimonidine 0.15%, Brimonidine 0.075%, Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

NCT02813265
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
918 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 9, 2026, 5:02 PM EDT
Recruiting Phase 1 Interventional

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

NCT07041099
View directory record Official record
Conditions
Sjögren, Sjogren Disease, Sjogren's Syndrome
Interventions
CLN-978
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Orlando, Florida • Brooklyn, New York • Memphis, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Results available

Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration

NCT00877032
View directory record Official record
Conditions
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
Interventions
RN6G, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Glendale, California • Inglewood, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 9, 2026, 5:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

NCT02422407
View directory record Official record
Conditions
Healthy, Sicca Syndrome, Sjögren's Syndrome
Interventions
Biopsy
Procedure
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
4
States / cities
Hartford, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 9, 2026, 5:02 PM EDT
Completed No phase listed Observational

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

NCT02463344
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
MA09-hRPE
Biological
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With DED

NCT03616899
View directory record Official record
Conditions
Kerato Conjunctivitis Sicca
Interventions
KPI-121 Ophthalmic Suspension, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
81
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects

NCT01748578
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005-1, EBI-005-1 Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 8, 2013 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

T30 for Astigmatism in Digital Device Users

NCT06266728
View directory record Official record
Conditions
Contact Lens Complication, Astigmatism, Refractive Errors
Interventions
Total30 for Astigmatism Contact Lenses
Device
Lead sponsor
Southern College of Optometry
Other
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Pittsburg, Kansas • Coldwater, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 9, 2026, 5:02 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

NCT03527212
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
SJP-0035 0.001%, Placebo
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Chandler, Arizona • Sun City, Arizona • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 9, 2026, 5:02 PM EDT
Recruiting No phase listed Observational

Comparative Assessment of Lipid Layer Thickness Measurements

NCT07579130
View directory record Official record
Conditions
Dry Eye
Interventions
LipiView, Omnicad, Bruder Ocular Surface Analyzer
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 9, 2026, 5:02 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT01577381
View directory record Official record
Conditions
Age-Related Maculopathy
Interventions
RN6G, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
83
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 3 Interventional

Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome

NCT00025818
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic
Interventions
Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Waterbury, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 9, 2026, 5:02 PM EDT
Not listed Phase 1 Interventional

A Usability Study of iTEAR100 For Combined EyeLid Microblepharoexfoliation and Neurostimulation

NCT06235450
View directory record Official record
Conditions
MicroBlepharoexfoliation, NuLids, iTEAR100, iLIDS100, Blepharitis, Dry Eye Syndrome
Interventions
iLIDS100
Device
Lead sponsor
Olympic Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Issaquah, Washington
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 9, 2026, 5:02 PM EDT
Completed Phase 4 Interventional

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

NCT02139033
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Retaine™
Drug
Lead sponsor
Ocusoft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 9, 2026, 5:02 PM EDT